CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard ...
According to preliminary data from a multi-institution Phase III trial intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when ...
Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...
Role of induction chemotherapy with docetaxel+cisplatin+5-FU (DCF) followed by radiotherapy for patients with inoperable head and neck cancer to observe local control Target delineation, area coverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results